-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Esperion Therapeutics, Maintains $5 Price Target

Benzinga·04/25/2025 10:21:18
Listen to the news
Needham analyst Serge Belanger reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Buy and maintains $5 price target.